| Literature DB >> 26754609 |
Zekun Liu1, Junpeng Zhao1, Weichen Li1, Li Shen1, Shengbo Huang2, Jingjing Tang2, Jie Duan2, Fang Fang2, Yuelong Huang1, Haiyan Chang2, Ze Chen2, Ran Zhang1.
Abstract
The Influenza A virus is a great threat for human health, while various subtypes of the virus made it difficult to develop drugs. With the development of state-of-art computational chemistry, computational molecular docking could serve as a virtual screen of potential leading compound. In this study, we performed molecular docking for influenza A H1N1 (A/PR/8/34) with small molecules such as quercetin and chlorogenic acid, which were derived from traditional Chinese medicine. The results showed that these small molecules have strong binding abilities with neuraminidase from H1N1 (A/PR/8/34). Further details showed that the structural features of the molecules might be helpful for further drug design and development. The experiments in vitro, in vivo have validated the anti-influenza effect of quercetin and chlorogenic acid, which indicating comparable protection effects as zanamivir. Taken together, it was proposed that chlorogenic acid and quercetin could be employed as the effective lead compounds for anti-influenza A H1N1.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26754609 PMCID: PMC4709578 DOI: 10.1038/srep19095
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The sequence and structural alignment for the NA from A/PR/8/34 H1N1 and A/Brevig Mission/1/1918 H1N1.
(A) The sequence alignment result. (B) The structural alignment result. The details for structural alignment were presented in (C,D).
Figure 2The top15 small molecules with high binding free energies with NA, while zanamvir served as the control.
The energies for the binding between the small molecules and NA.
| Molecules | (vdW + Hbond + desolv) energy(kcal/mol) | Electrostatic energy (kcal/mol) | Total Internal energy (kcal/mol) | The best docking energy (kcal/mol) | Inhibition constant (nM) |
|---|---|---|---|---|---|
| Zanamvir | −11.1 | −3.1 | −17.92 | −11.24 | 5.73 |
| Quercetin | −8.09 | −0.59 | −19.65 | −10.23 | 31.97 |
| Chlorogenic acid | −11.1 | −2.49 | −22.43 | −11.05 | 7.98 |
Figure 3The structures of zanamvir (A), quercetin (B), chlorogenic acid (C), and the details of the binding between NA and zanamvir (D), quercetin (E), chlorogenic acid (F).
The chemical informatics analyses of zanamvir, quercetin and chlorogenic acid.
| Molecules | MW | LogP | tPSA | Rotatable bonds | HB donors | HB acceptors | Oral Bioavailability (VEBER) | Oral Bioavailability (EGAN) |
|---|---|---|---|---|---|---|---|---|
| Zanamvir | 333.32 | −2.98 | 202.79 | 7 | 9 | 11 | ||
| Quercetin | 302.24 | 2.17 | 134.2 | 1 | 5 | 7 | Good | Good |
| Chlorogenic acid | 354.31 | −0.42 | 167.6 | 5 | 5 | 9 | Good | Good |
The residues for the H-bonds between the small molecules and NA.
| Molecules | H-bond residues |
|---|---|
| Zanamvir | ARG118, ASP151, ARG152, ARG224, GLU276, GLU277, ARG292, ASN294, GLY348, ARG371, ARG406 |
| Quercetin | ARG118, ASP151, ARG152, LYS211, ARG224, GLY244, GLU276, GLU277, ARG292, TYR406 |
| Chlorogenic acid | ARG118, ASP151, ARG152, ARG224, GLU277, ARG292, ARG371 |
Figure 4The summary of the experimental results for cytopathic effect (CPE) (A), mean fluorescence intensity (B), effect rate (C), death protection rate (D) and lung index (E).
Validation of NA inhibition ability for small molecules.
| Concentration (μg/ml) | Mean CPE ± S.D. | ER(%) | Mean fluorescence intensity (A.U ± S.D.) | |
|---|---|---|---|---|
| Chlorogenic acid | 50 | 2.00 ± 0.00*** | 52.7*** | 2.25 ± 0.39*** |
| 25 | 2.25 ± 0.50*** | 43.8*** | 3.31 ± 0.25*** | |
| 12.5 | 3.00 ± 0.50** | 25.6** | 4.11 ± 0.32*** | |
| 6.25 | 3.33 ± 0.50* | 17.8* | 4.43 ± 0.38*** | |
| 3.125 | 3.67 ± 0.58 | 10.2 | 4.75 ± 0.45** | |
| 1.563 | 4.00 ± 0.00 | 5.3 | 5.67 ± 0.57 | |
| Quercetin | 50 | 1.67 ± 0.00*** | 59.3*** | 1.74 ± 0.16*** |
| 25 | 2.00 ± 0.00*** | 50.6*** | 2.67 ± 0.20*** | |
| 12.5 | 2.33 ± 0.58*** | 41.5** | 3.50 ± 0.26*** | |
| 6.25 | 3.00 ± 0.00** | 26.3** | 4.34 ± 0.31*** | |
| 3.125 | 3.33 ± 0.58* | 19.4* | 4.63 ± 0.41*** | |
| 1.563 | 3.33 ± 0.58* | 17.7* | 5.48 ± 0.52* | |
| Zanamvir | 50 | 0.00 ± 0.00*** | 87.3*** | 1.24 ± 0.11*** |
| 25 | 0.00 ± 0.00*** | 84.1*** | 1.73 ± 0.15*** | |
| 12.5 | 0.67 ± 0.58*** | 79.6*** | 2.20 ± 0.25*** | |
| 6.25 | 1.25 ± 0.50*** | 68.8*** | 3.27 ± 0.29*** | |
| 3.125 | 2.67 ± 0.58*** | 35.3** | 3.34 ± 0.40*** | |
| 1.563 | 2.75 ± 0.50** | 31.7** | 5.35 ± 0.48** | |
| Placebo | – | 4.00 ± 0.00 | – | 7.54 ± 0.61 |
| Normal | – | 0.00 ± 0.00 | – | 1.71 ± 0.14 |
*p < 0.05, **p < 0.01, ***p < 0.001, the values were compared with placebo controls.
In vivo validation of anti-influenza abilities of quercetin and chlorogenic acid.
| Treatment | Dose (mg/kg/d) | Survivors/totals (%) | Mean lung parameters | |
|---|---|---|---|---|
| Lung Index ± S.D. (%) | Lung indexInhibition % | |||
| Zanamivir | 960 | 10/10 (100)*** | 0.65 ± 0.10*** | 34.0 |
| 480 | 9/10 (90)*** | 0.74 ± 0.11*** | 25.3 | |
| 240 | 7/10 (70)*** | 0.81 ± 0.11** | 18.3 | |
| Quercetin | 960 | 8/10 (80)** | 0.73 ± 0.07*** | 26.3 |
| 480 | 7/10 (70)** | 0.82 ± 0.03** | 16.5 | |
| 240 | 6/10 (60)* | 0.84 ± 0.02** | 14.7 | |
| Chlorogenic acid | 960 | 5/9 (55.6)* | 0.79 ± 0.10** | 20.2 |
| 480 | 5/10 (50) | 0.84 ± 0.05** | 14.4 | |
| 240 | 4/10 (40) | 0.87 ± 0.11* | 12.2 | |
| Placebo | — | 1/10 (10) | 0.99 ± 0.13 | — |
| Normal | — | 10/10 (100) | 0.56 ± 0.07 | — |
*p < 0.05, ** p < 0.01, ***p < 0.001, the values were compared with placebo controls.